ArticleAesthetic surgery journal. Open forum2026
A Real-World Study of Patient and Physician Satisfaction With Repeated AbobotulinumtoxinA Treatment of Glabellar Lines in Chinese Patients.
Article in Aesthetic surgery journal. Open forum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: AbobotulinumtoxinA (aboBoNT-A; Dysport Objectives: Primary objective: to assess patient satisfaction following 3 cycles of aboBoNT-A treatment for moderate-to-severe GLs in a real-world setting. Secondary variables included effectiveness, patient and physician satisfaction in each cycle, and injection practice details. Methods: In this non-interventional, multicenter study conducted in China, participants received 3 injection cycles of aboBoNT-A in the GL area, 3 to 6 months apart, with follow-up at Week 3, before the next treatment, and at end-of-study. Assessments included satisfaction questionnaires, GL wrinkle severity, and safety. Results: At 3 weeks after the third injection, 100% of patients ( Conclusions: All patients were satisfied with aboBoNT-A GL treatment after 3 injection cycles in this Chinese real-world study. As supported by multiple outcome measures, both patients and physicians reported high satisfaction with treatment and long-lasting improvement in wrinkle severity across single or repeat cycles. Treatment was well tolerated. Level of Evidence 4 Therapeutic: For image description, please refer to the figure legend and surrounding text.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.